UK researchers warn of only ’50 percent’ success for COVID vaccine trial
Developing a vaccine for the coronavirus could prove difficult due to the declining number of infections, researchers in Britain have warned.
Reports that Oxford was proceeding to the second stage of human trials for its coronavirus vaccine, which would see the number of participants rise to 10,000 people, were met with optimism. Oxford’s Jenner Institute is working with drug company Astra Zeneca to develop a vaccine.
The government projected that the vaccine, if successful, could deliver 30 million doses by September. However, scientists involved with the study have given interviews with separate London-based newspapers warning that initial projections may prove to be optimistic.
